^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1d
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    6d
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=217, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2028
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    8d
    Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA (clinicaltrials.gov)
    P1, N=9, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • Chr t(11;14) • CD20 negative
    8d
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA (clinicaltrials.gov)
    P1, N=9, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    9d
    A Recently Recognized and Underdiagnosed Entity of Splenic Diffuse Red Pulp Small B-Cell Lymphoma: A Report of Two Cases. (PubMed, Cureus)
    Case 1 was a 65-year-old woman diagnosed in 2017 with SMZL and treated with rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (or prednisolone) (R-CHOP), achieving complete remission, who presented nine years later with recurrent hyperlymphocytosis at 10.8 × 109/L with villous appearance, massive splenomegaly, and systemic symptoms...The patient was treated with rituximab-bendamustine and achieved complete remission...Rituximab monotherapy was followed by rapid improvement, with normalization of the lymphocyte count to 2.13 × 109/L and regression of splenomegaly from the first cycle. These observations highlight the importance of combining lymphocyte immunophenotyping and bone marrow aspiration in isolated splenomegaly with villous lymphocytes on blood smear to avoid underdiagnosis of this new histopathological entity and therefore guide therapeutic management in the absence of guidelines.
    Journal
    |
    CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • ITGAX (Integrin Subunit Alpha X)
    |
    CD19 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • bendamustine
    12d
    A Phase I Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive ALL (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, Wake Forest University Health Sciences
    New P1 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    CD19 positive
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • LP-118
    23d
    The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder. (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    23d
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Baylor College of Medicine | Trial completion date: Feb 2035 --> May 2040 | Trial primary completion date: Jun 2026 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • KUR-502
    28d
    Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Ruijin Hospital
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    28d
    CAR-p40-T: Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Shenzhen University General Hospital
    New P1/2 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1m
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    1m
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive